Ardena
Ghent, Belgium
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
○ MHRA GMP
Quick Facts: Ardena
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Ghent, Belgium
- Modalities
- Small Molecule API, Solid-State Research, HPAPI, PROTACs / Molecular Glues, Nanomedicine / LNP, Drug Product (Oral, Injectable, Semi-solid), CMC Regulatory, Bioanalysis
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Ardena
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesSmall Molecule API, Solid-State Research, HPAPI, PROTACs / Molecular Glues, Nanomedicine / LNP, Drug Product (Oral, Injectable, Semi-solid), CMC Regulatory, Bioanalysis
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (8 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press10 articles
Broad modality coverage (8 modalities)
Recent News 10 articles
Sweden's Nanologica acquires API facility from CDMO Ardena, brings team of 45 on board - Fierce Pharma
Ardena’s US plant buy pays off as CDMO endures rough geopolitical waters - Fierce Pharma
Ardena Completes Acquisition of Advanced Drug Product - GlobeNewswire
Ardena divests Södertälje drug substance site to Nanologica - European Pharmaceutical Review
Belgian CDMO Ardena gets new private equity owners - BioPharma Dive
Ardena Expands with Key U.S. Facility Buy - Manufacturing Today
Precision Medicine in Focus: Ardena’s Strategic Growth & Innovation Under CEO Jeremie Trochu - Contract Pharma
10 CDMO Up & Comers - Genetic Engineering and Biotechnology News
Ardena Strengthens Executive Team to Drive its Next Phase of Growth - BioSpace
Ardena Names Dr. Ariane de Ganck as Chief Scientific Officer - Contract Pharma
Frequently Asked Questions About Ardena
What is Ardena's CDMO Signal Score?
Ardena has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Ardena for a manufacturing program?
Use the free AI matchmaker to compare Ardena against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Fermion (Orion Group)
Espoo, Finland
Small Molecule API, HPAPI, Semi-solid drug product (creams, gels, ointments), Hormonal products
Veranova
Devens, MA (US HQ); multiple global sites
Small Molecule API, HPAPI, ADC payload/linker, Oligonucleotide, Peptide
Sai Life Sciences
Hyderabad, India
Small Molecule API, Complex Small Molecules, HPAPI, ADC, Peptides, Oligonucleotides, Lipids / LNP, Intermediates, Drug Discovery (CRO)
Cambrex Corporation
East Rutherford, NJ
Small Molecule API, HPAPI, Controlled Substances, Oral Solid Dose, Solid State Research, Particle Engineering, Drug Product (OSD), Controlled Release
Abzena
Raleigh, NC
ADC, AOC, RDC, Biologics, mAb, HPAPI, Bioconjugation